Raksaseri P, Chatsudthipong V, Muanprasat C, Soodvilai S. Activation of liver X receptors reduces CFTR-mediated Cl Ϫ transport in kidney collecting duct cells. Am J Physiol Renal Physiol 305: F583-F591, 2013. First published May 29, 2013 ; doi:10.1152/ajprenal.00579.2012.-Liver X receptors (LXRs) are transcription factors belonging to the nuclear receptor super family, which act as regulators of lipid and glucose metabolism. However, LXRs have been shown to regulate the function of transporters in the kidney, including the Na-Pi cotransporter, organic anion transporter, and epithelial Na ϩ channel. In this report, we demonstrated the ability of LXR ligands, both endogenous [22 (R)-hydroxycholesterol] and synthetic (T0901317 and GW3965), to reduce CFTR-mediated Cl Ϫ secretion in a type I Madin-Darby canine kidney (MDCK) cell line and in murine primary inner medullary collecting duct (IMCD) cells, based on measurements of [Arg 8 ]-vasopressin-induced Cl Ϫ current. However, treatment of MDCK cell monolayers with 5 M T0901317 for 24 h did not alter ouabainsenstive current or Na ϩ -K ϩ -ATPase-␣ protein content. Furthermore, basolateral membranes permeabilization of MDCK cell monolayers still resulted in a decrease in apical Cl Ϫ current stimulated by both [Arg 8 ]-vasopressin and 8-cholorophenyl-thio-cAMP, indicating that the factor(s) encoded by the target gene(s) of agonist-activated LXRs might be located at the apical membrane. Western blot analysis revealed that inhibition of Cl Ϫ secretion occurred via a decrease in CFTR protein, which was not due to downregulation of its mRNA expression. In addition, both synthetic LXR agonists significantly retarded the growth of forskolin-induced cysts formed in MDCK cells cultured in collagen gel. This is the first evidence showing that ligand-activated LXRs are capable of downregulating CFTR-mediated Cl Ϫ secretion of kidney cells and of retarding cyst growth in a MDCK cell model. vasopressin; polycystic kidney disease; regulation; nuclear receptors; cystic fibrosis transmembrane conductance regulator CYSTIC FIBROSIS (CF) transmembrane conductance regulator (CFTR) is a cAMP-regulated Cl Ϫ channel glycoprotein belonging to ATP-binding cassette (ABC) transporter subfamily 7 (ABCC7) (29) . Mutation of the ABCC7 gene impairs CFTR function, leading to autosomal recessive CF (28, 36) . CF patients ultimately succumb to respiratory failure due to blockage of the airway stemming from the secretion of abnormally viscous fluid. On the other hand, in polycystic kidney disease (PKD), an increase in CFTR-mediated Cl Ϫ secretion of renal tubular epithelial cells enhances cyst expansion (4, 16) . CFTR is localized at the epithelial cell apical plasma membrane of the airway epithelia, small intestine, pancreas, bile duct, epididymis, and kidney (9, 28) . In the latter organ, CFTR mRNA is expressed in nephron segments, where it is involved in Cl Ϫ secretion of principal cells of cortical and medullary collecting ducts (21) . The opening of CFTR Cl Ϫ channel requires phosphorylation of the regulatory (R) domain by PKA and ATP hydrolysis by nucleotide-binding domains (25) .
Liver X receptors (LXRs) are ligand-activated transcription factors belonging to the superfamily of nuclear receptors, consisting of two isoforms, LXR␣ and LXR␤ (11) . LXR␣ is synthesized in the liver, spleen, adipose tissue, intestine, lung, and kidney, whereas LXR␤ is present in all tissues so far examined (1, 37) . LXRs function as sensors of intracellular cholesterol and glucose (7, 19, 27, 39) . LXR␣ and LXR␤ form heterodimers with the retinoic X receptor, which then bind to promoters of target genes, thereby modulating their expression (12, 41) . To maintain intracellular cholesterol homeostasis, LXRs stimulate cholesterol efflux by upregulating expression of ABC transporter A1 in the liver and ABC transporters G5 and G8 in the intestine (24, 27) . A recent study has reported that activation of sterol regulatory element-binding protein (SREBP)-1c expression by insulin requires LXRs, indicating that the action of insulin on energy metabolism may require a function of LXRs (8) .
Although LXRs are present throughout the nephron (13, 22, 40) , their role in the regulation of kidney function is still largely unknown. Recent studies have shown that LXRs regulate renal transporters and ion channels, including the Na-P i cotransporter, organic anion transporter (OAT)1, and epithelial Na ϩ channel (ENaC) (5, 13, 31) . Taken together, these results suggest that LXRs have a role in the regulation of renal electrolyte transport. In the present study, we provide evidence of a previously unreported role of LXRs in the inhibition of CFTR-mediated Cl Ϫ secretion in both murine primary collecting duct and Madin-Darby canine kidney (MDCK) cells. In addition, we show that activated LXRs retard cyst growth in a MDCK cell model.
MATERIALS AND METHODS
Animals. Male C57BL6 mice (7-8 wk old, National Laboratory Animal Center, Mahidol University, Bangkok, Thailand) were maintained on a 12:12-h light-dark cycle with ad libitum access to standard laboratory pellet containing 1.0% calcium and 0.9% phosphorus (CP) and distilled water. All animal experimental procedures were approved by the Laboratory Animal Ethical Committee of the Faculty of Science, Mahidol University, Bangkok, Thailand.
Chemicals. Amphotericin B, amiloride, 8-cholorophenyl-thio-cAMP (CPT-cAMP), cycloheximide, forskolin, GW3965, 22(R)-hydroxycholesterol [22(R)-HC], hyaluronidase, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), ouabain, and T0901317 were purchased from Sigma-Aldrich. Collagenase type I was from Worthington Biochemical, [Arg 8 ]-vasopressin (AVP) was from Calbiochem, protease inhibitor cocktail was from Roche Diagnostics (Mannheim, Germany), and EZ-Link Sulfo-NHS-SS-Biotin and streptavidin-agarose resins were from Pierce. Polyclonal rabbit anti-CFTR antibody, monoclonal mouse anti-␤-actin, and goat horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antibodies were obtained from Cell Signaling Technology. Mouse anti-SREBP-1c and mouse anti-Na ϩ -K ϩ ATPase-␣ monoclonal antibodies from Novus Biologicals. Mouse polyclonal anti-CFTR and rabbit polyclonal anti-LXR␣ and anti-LXR␤ antibodies were from Abcam. All other chemicals used were of analytic grade.
Cell culture. The type I MDCK cell line was a generous gift from Dr. David N. Sheppard (University of Bristol, Bristol, UK). Cells were grown in DMEM-F-12 medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin and insulin-transferrin-selenium at 37°C in a humidified incubator under an atmosphere of 5% CO 2. Cells were seeded on Snapwell insert (Corning Life Sciences) at a density of 5 ϫ 10 5 cells/well. Medium was replaced every other day. The transepithelial resistance (TER) of confluent cells was measured using an EVOM 2 epithelial volt-ohmmeter (World Precision Instruments). Confluent monolayers that achieved a high resistance phenotype (TER Ͼ 1,000 ⍀·cm 2 ) were polarized by removal of the culture medium to form an air-liquid interface to enhance the expression of CFTR at the MDCK apical membrane (2) . To test the effects of LXR agonists, monolayers were placed in serum-free medium without phenol red for 12 h to eliminate any effect from serum.
Primary culture of mouse renal inner medullary collecting duct cells. Primary culture of mouse renal inner medullary collecting duct (IMCD) cells was established as previously described (32) . In brief, the renal medulla was dissected, minced, and digested for 1 h in 10 ml DMEM containing 0.2% collagenase type I, 0.2% hyaluronidase, and 0.25% trypsin-EDTA at 37°C. Osmotic shock (100 mosmol/kg H 2O) was induced by the addition of 20 ml sterile distilled water into the medium and an incubation for 20 min to eliminate noncollecting duct cells. Cells were then sedimented at 1,500 rpm for 5 min, resuspended in fresh DMEM containing 10% FBS, 20 ng/ml EGF, and 100 U/ml penicillin-streptomycin, and plated onto a Snapwell insert. Confluent primary IMCD monolayers that generated TER Ͼ 500 ⍀·cm 2 were used for further experiments.
Electrophysiological analysis. Short-circuit current (Isc) was used to monitor net ion flux across monolayers of MDCK cells and primary cultures of IMCD cells. Confluent monolayers with high resistance (as described above) were transferred to an Ussing chamber, and the spontaneous potential difference across the monolayer was clamped at 0 mV. Isc was recorded continuously using a VC600 voltage clamp (Physiologic Instruments) with Ag/AgCl electrodes and a 3 M KCl agar bridge. Apical and basolateral sides of the monolayer were exposed to physiological solution [containing (in mM) 117 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 MgSO4, 2.5 CaCl2, 1.2 KH2PO4, and 11 D-glucose] at 37°C and bubbled with a gas mixture of 95% O2-5% CO2 to maintain pH of the solution at 7.4. Positive Isc indicates active transport of a cation (Na ϩ ) from the apical to basolateral side of the monolayer or transport of an anion (Cl Ϫ ) from the basolateral to apical side (32) . To measure Cl Ϫ current (ICl), Na ϩ current, which primarily is transported through ENaCs, was inhibited by the addition of amiloride (100 M) into the apical bathing solution, and the positive Isc measured under this condition was that of Cl Ϫ transport. To stimulate CFTR-mediated Cl Ϫ secretion, AVP (20 nM) or CPTcAMP was added to the basolateral side after the addition of amiloride.
Apical Cl Ϫ transport measurement. Confluent MDCK cell monolayers were mounted into an Ussing chamber and bathed asymmetrically with physiological buffer [containing (in mM) 130 NaCl, 2.7 KCl, 1.5 KH2PO4, 1 CaCl2, 0.5 MgCl2, 10 Na-HEPES (pH 7.3), and 10 glucose] for the basolateral hemichamber, whereas the apical hemichamber was filled with physiological buffer in which 65 mM NaCl was replaced with 65 mM sodium gluconate to establish a Cl Ϫ gradient. To measure apical ICl, the basolateral membrane of the MDCK cell monolayer was permeabilized using amphotericin B (250 g/ml) for 30 min (26) followed by the addition of 100 M amiloride to the apical side to inhibit ENaC-mediated Na ϩ flux. After Isc was stable, Cl Ϫ secretion was stimulated by the addition of AVP (20 nM) or CPT-cAMP (100 M) to the basolateral chamber.
Measurement of Na
-ATPase transport activity. Na ϩ -K ϩ -ATPase activity was determined by ouabain-sensitive current measurement in the Ussing chamber as previously described (23, 31) . Briefly, confluent cell monolayers grown on Snapwell filters were mounted in a chamber bathed symmetrically with physiological medium. The apical membrane of the monolayers was permeabilized by 250 g/ml amphotericin B for 30 min to allow the free transport of ions from the apical side into the cell. Positive Isc was established because Na ϩ -K ϩ -ATPase produced a net positive charge at the basolateral side of the cell monolayer (3 Na ϩ were extruded while 2 K ϩ were uptaken into the cells). After positive I sc became stable, 1 mM ouabain, an inhibitor of Na ϩ -K ϩ -ATPase, was added to the basolateral side of monolayers. The change in I sc after the addition of ouabain reflected the activity of Na ϩ -K ϩ -ATPase. Cell viability assay. Cell viability was determined using an MTT assay (33) . In brief, MDCK cells were seeded in a 96-well plate at a density of 2 ϫ 10 4 cells/well. After growth for 24 h in a humidified incubator at 37°C under an atmosphere of 5% CO 2, cells were incubated further for 24 or 96 h in serum-free medium containing vehicle (0.01% DMSO) or LXR agonists (T0901317 and GW3965) at the indicated concentrations. The medium was then removed, and cells were incubated with 20 l MTT (5 mg/ml) for 4 h at 37°C. After removal of the medium, a 100-l aliquot of 100% DMSO was added, and absorbance at 590 nm was measured (BMG spectrophotometer, LABTECH).
RT-PCR. Total RNA was extracted from MDCK and primary IMCD cells using TRIzol reagent (Invitrogen) according the manufacturer's instructions. The amount and quality of RNA were determined using a Nanodrop 2000 spectrophotometer (Thermo Scientific). RT-PCR was performed using the iScript Select cDNA synthesis kit (Bio-Rad Laboratories) and Fast-Start Taq kit (Roche Diagnostics). Primers specific for LXR␣ and LXR␤ mRNA were designed (Biodesign) based on sequences in the National Center for Biotechnology Information database. Canine LXR␣ primers were (forward) 5=-GTCAG-CAGCGCTTTGCCCAC-3= and (reverse) 5=-CTAGGAAGCAGCCAG-GTGCC-3= (predicted amplicon of 649 bp), canine LXR␤ primers were (forward) 5=-GGCCATGAGCTGTGCCGTGT-3= and (reverse) 5=-GTGGGCAAAACGCTGCTGGC-3= (predicted amplicon of 552 bp), murine LXR␣ primers were (forward) 5=-TCCATCAACCACCCCCAC-GAC-3= and (reverse) 5=-CAGCCAGAAAACACCCAACCT-3= (predicted product size of 328 bp), and murine LXR␤ primers were (forward) 5=-GCTCAGGAGCTGATGATCCA-3= and (reverse) 5=-GCGCTT-GATCCTCGTGTAG-3= (predicted amplicon of 567 bp). The following thermocycling conditions were used: 95°C for 5 min, 95°C for 1 min, 30 cycles of 58.5°C for 1 min (for canine) or 60°C for 30 s (for murine) and 72°C for 60 s, and a 10-min final heating at 72°C. Amplicons were separated by 2% agarose gel electrophoresis and visualized by staining with ethidium bromide.
Quantitative PCR. Total RNA from mouse IMCD cells was extracted using TRIzol reagent (Invitrogen) and cDNA synthesized using the iScript cDNA synthesis kit (Bio-Rad). Primers used for amplification of mouse CFTR cDNA were (forward) 5=-GCTTTATCTC-CAAACTCTTCTTCA-3= and (reverse) 5=-GCTTGTTCTCTGTC-CCATTCTC-3=, primers for mouse ␤-actin (as an internal standard) were (forward) 5=-TGTGGATCAGCAAGCAGGAGT-3= and (reverse) 5=-AAACGCAGCTCAGTAACAGTCC-3=, primers used for canine CFTR cDNA were (forward) 5=-GGAAAGAGAATGGGACAG-AGA-3= and (reverse) 5=-CCAAGTAAGAGAGGCTGGATTG-3=, and primers used for canine ␤-actin (as an internal standard) were (forward) 5=-GATTCTCTAGAGGCTGGCAAG-3= and (reverse) 5=-TTGGG-TAAGACAGGAAAGTGG-3=. Quantitative PCR of the mouse CFTR mRNA expression level was performed using KAPA SYBR FAST master mix (KAPA Biosystem) in ABI Prism 7500 Sequence Detection System (Applied Biosystems), and relative quantification was determined using the 2 Ϫ⌬⌬CT method (where CT is threshold cycle) (17) . Western blot analysis. MDCK and primary IMCD cells grown in six-well plates were lysed in ice-cold Triton X-100 lysis buffer [50 mM Tris·HCl (pH 7.4), 150 mM NaCl, 1 mM NaF, 1mM EDTA, 1 mM sodium orthovanadate, 100 M PMSF, protease inhibitor cocktail, and 1% Triton X-100] for 20 min at 4°C. After centrifugation at 12,000 rpm for 20 min at 4°C, 50 g of supernatant cell lysate protein were separated by 10% SDS-PAGE and transferred to a Hybond-ECL nitrocellulose membrane (Amersham Biosciences). The membrane was incubated in 5% nonfat dry milk for 1 h and then with rabbit polyclonal antibodies against CFTR (1:1,000 dilution), mouse monoclonal antibodies against SREBP-1c (2 g/ml), mouse monoclonal antibodies against Na ϩ -K ϩ -ATPase-␣ (1:1,000 dilution), rabbit polyclonal antibodies against LXR␣ and LXR␤ (1:1,000 dilution), or ␤-actin (1:2,000 dilution) overnight at 4°C followed by an incubation with secondary HRP-conjugated goat anti-rabbit IgG (1:4,000 dilution) or HRP-conjugated goat anti-mouse IgG (1:2,000 dilution) for 1 h at room temperature. Immunoreactive bands were detected by chemiluminescence, recorded on hyperfilm using a Western lightning plus-ECL detection kit (Perkin-Elmer), and quantified using ImageJ analysis software.
Cell surface expression of CFTR protein. CFTR in the cell membrane was isolated by membrane-impermeable biotinylation reagents. MDCK cells were incubated on ice with EZ-Link Sulfo-NHS-SSBiotin (Pierce) for 30 min followed by a wash with 3 ml of PBSCa 2ϩ -Mg 2ϩ containing 0.1 M glycine buffer. Cells were further incubated on ice with the same solution for 20 min to ensure complete quenching of the unchanged EZ-Link Sulfo-NHS-SS-Biotin. They were then harvested by the addition of buffer containing (in mM) 10 Tris·HCl (pH 7.5), 150 NaCl, 1 EDTA, 0.1% SDS, and 1% Triton X-100 with protease inhibitor cocktail for 20 min at 4°C. Samples were centrifuged at 12,000 rpm for 20 min, and supernatants were collected and incubated with 150 l streptavidin-agarose beads (Pierce) overnight at 4°C. Beads were then washed three times with lysis buffer and once with PBS. Proteins were released from the beads by an incubation with buffer containing 100 mM DTT for 30 min at room temperature. Membrane expression of CFTR was detected by Western blot analysis.
MDCK model of cyst formation and growth. MDCK cells were cultured in collagen gel in the presence of forskolin (cAMP activator) to stimulate cyst formation using the method of McAteer et al. (18) . In brief, each well of a 24-well plate was incubated with 0.4 ml of ice-cold collagen solution (3.0 mg/ml) supplemented with 10% of 10ϫ minimum essential medium, 10 mM HEPES (pH 7.4), 27 mM NaHCO 3, 100 U/ml penicillin, and 100 g/ml streptomycin. After collagen solution was added into the 24-well plate, the collagen was allowed to form a semisolid gel for 10 min. Medium containing the cell suspension (800 cells) was added into the semisolid gel. This technique prevents dropping of the cells into the bottom of the well and, therefore, allows MDCK cells to be embedded in the collagen gel layer. The cell embedded-collagen gel was further incubated at 37°C for 90 min in a humidified incubator under an atmosphere of 5% CO2 to allow gel polymerization. In addition, medium containing forskolin was added on top of the gel to stimulate cyst formation. The medium (with forskolin) was replaced every day. The presence of cysts from day 6 was detected using a phase-contrast microscope (ϫ100 magnification). To test the effect of LXR agonists on cyst growth, 0.01% DMSO (control) and LXR agonists (5 M T0901317 and 2 M GW3965) were added into culture medium from day 6 onward, and fresh media containing the test compounds were replaced every day. At least 30 cysts with a diameter of Ͼ50 m (photographed using ImageJ software) were selected for each experimental condition. Photographs of individual cysts were taken every other day from day 6 to day 12, and cyst size was compared between vehicle-and LXR agonist-treated groups.
Statistical analysis. Results are presented as means Ϯ SE. Statistical differences between control and treatment were determined using a Student's unpaired t-test or one-way ANOVA followed by the Tukey test. Differences were considered statistically significant when P Ͻ 0.05.
RESULTS

Expression of LXR␣ and LXR␤ in MDCK cells.
We first verified whether the MDCK cells used in this study express LXRs. Expression of mRNA and protein of LXR␣ and LXR␤ isoforms in MDCK cells was determined using RT-PCR and Western blot analysis, respectively. We found that both mRNA and protein of LXR␣ and LXR␤ isoforms were detected in these cells (Fig. 1A) . LXR activation in MDCK cells after treatments with LXR agonists was confirmed by the detection of SREBP-1c protein, a product of the LXR target gene. Western blot analysis revealed that 5 M T0901317 and 2 M GW3965 increased the expression of SREBP-1c protein (Fig.  1B) . These results indicate that T0901317 and GW3965 exerted LXR activation in MDCK cells. In addition, CFTRmediated Cl Ϫ transport induced by AVP and cAMP in MDCK cells was verified using an inhibitor of CFTR, glycine hydrazide-101. The results demonstrated that the addition of 50 M glycine hydrazide-101 abolished the stimulatory effect of AVP and CPT-cAMP (Fig. 1C) . Taken together, our results support the notion that CFTR mediates AVP-and cAMP-induced Cl Ϫ transport in MDCK cells.
Effect of LXR agonists on AVP-induced Cl
Ϫ secretion in MDCK cells. Confluent MDCK cell monolayers were preincubated with various concentrations of LXR agonists (T0901317 and GW3965) for 24 h and then placed in the Ussing chamber for a 30-min equilibration period followed by the addition of 100 M amiloride to inhibit ENaC-mediated Na ϩ transport. I Cl was measured after the addition of 20 nM AVP into the basolateral hemichamber. Incubation with LXR agonists for 24 h led to a decrease in AVP-stimulated I Cl in a dose-dependent manner ( Fig. 2A) . In addition, after an incubation of MDCK cell monolayers for 24 h with 50 M 22(R)-HC, an endogenous LXR ligand, AVP-induced Cl Ϫ secretion was reduced to 65.2 Ϯ 10.3% of the vehicle-treated monolayer. The inhibitory effect of T0901317 on I Cl was observed after 12 h of treatment, but that of GW3965 required a longer exposure, i.e., for 24 h (Fig. 2B) . However, an extension of the incubation time did not lead to a further decrease in I Cl .
Effect of LXR agonists on cell viability. To determine whether the inhibitory effects of LXR agonists on AVPinduced Cl
Ϫ secretion in MDCK cells were due to their cytotoxicity, cell viability was assessed using a MTT assay and measurement of TER. Incubation with 5 M T0901317 or 2 M GW3965 for 24 h did not significantly decrease the cell viability of MDCK cells compared with the vehicle-treated control. Similarly, TER obtained from T0901317-and GW3965-treated monolayers was not significantly different from that of the vehicle-treated monolayer (Fig. 3) .
Effect of LXR agonist on apical I Cl in MDCK cell monolayers. The inhibitory effect of LXR agonists on AVPinduced Cl Ϫ transport could occur at either the basolateral membrane, intracellular signaling cascades, or the apical membrane. The contribution of the basolateral membrane on the inhibitory effect of LXR was, therefore, determined. The basolateral membrane of MDCK cell monolayers was permeabilized by 250 g/ml amphotericin B for 30 min followed by the addition of AVP (20 nM) or CPT-cAMP (100 M) to stimulate I Cl . AVP-and CPT-cAMP-induced apical I Cl of MDCK cell monolayers treated with T0901317 were significantly lower than that of the vehicle-treated control cell monolayer (Fig. 4) . These data suggest that the protein(s) encoded by target gene(s) of activated LXR is not located at the basolateral Effect of LXR agonist on Na ϩ -K ϩ -ATPase transport activity and protein expression in MDCK cells. To confirm that the basolateral membrane was not a target of LXR activation, the effect of LXR activation on Na ϩ -K ϩ -ATPase activity, a pump responsible for transepithelial Cl Ϫ transport, was determined. MDCK cell monolayers were mounted and incubated with physiological buffer in the Ussing chamber. Na ϩ -K ϩ -ATPase activity was measured by permeabilization of the apical membrane using amphotericin B followed by the addition of 1 mM ouabain. The change in I sc after the addition of ouabain represents the activity of Na ϩ -K ϩ -ATPase. It was found that there was no change in ouabain-sensitive current in the treated monolayer compared with the untreated control (Fig. 5A ). This result was consistent with the Western blot analysis, showing that T0901317 treatment did not alter protein expression of the Na ϩ -K ϩ -ATPase ␣-subunit (Fig. 5B) .
Effect of LXR agonist on mRNA and protein expression of CFTR in MDCK cells. To elucidate the mechanism underlying the decrease in Cl
Ϫ secretion induced by agonist-activated LXRs, the expression of mRNA and protein of CFTR during LXR activation was determined in MDCK cells. mRNA expression of CFTR after treatment with 5 M T0901317 was not significantly different compared with the vehicle-treated cell monolayer (Fig. 6A) . In contrast to mRNA expression, exposure of the cell monolayer to 5 M T0901317 resulted in decreases in both total and membrane CFTR protein expression levels (Fig. 6B) .
Effect of LXR agonist on CFTR-mediated Cl
Ϫ transport during inhibition of protein synthesis in MDCK cells. To investigate whether an inhibition of protein synthesis affects the action of LXR on CFTR-mediated Cl Ϫ secretion, we examined the effect of cycloheximide, an inhibitor of protein synthesis, on AVP-induced Cl Ϫ secretion. Confluent MDCK cell monolayers were preincubated for 12 h with vehicle or 100 nM cycloheximide. At the end of the preincubation period, vehicle-treated cells monolayers were further incubated for 24 h with vehicle or 5 M T0901317, whereas cycloheximidetreated cell monolayers were further incubated with cycloheximide alone or cycloheximide plus 5 M T0901317 for 24 h. At the end of the incubation, AVP-induced Cl Ϫ secretion was measured by I Cl . As shown in Fig. 7 , cycloheximide or T0901317 alone caused a significant inhibition of AVP-induced I Cl . Interestingly, the inhibitory effect of both T0901317 and cycloheximide was not additive. These results indicate that the target responsible for the inhibitory effect of LXRs might be at translational levels.
Effect of LXR agonist on Cl Ϫ secretion in primary IMCD cells. Primary IMCD cells were found to express both mRNA and protein of LXR␣ and LXR␤ (Fig. 8A) . As shown in Fig.  8B , incubation of primary IMCD cell monolayers with 5 M T0901317 for 24 h led to a significant decrease in I Cl compared with the untreated control cell monolayer. This reduction was related to a change in CFTR protein expression but not in mRNA expression (Fig. 8C) .
Effect of LXR agonists on MDCK cyst enlargement. As CFTR has been reported to mediate renal cyst growth (16) , the effect of LXR agonists on cyst growth generated from MDCK cells grown in collagen gel was investigated. Cysts (on day 6 of culture containing 10 M forskolin) were exposed to 5 M T0901317 or 2 M GW3965. The size of the vehicle-treated control cysts continuously increased, but the presence of T0901317 or GW3965 significantly retarded cyst size after day 10 of culture (Fig. 9, A and B) . In addition, exposure of MDCK cells to LXR agonists for 4 days did not alter cell viability. These data indicate that the inhibitory effect of LXR agonists on cyst enlargement was not caused by cytotoxicity.
DISCUSSION
The role of LXRs in cellular energy metabolism is well documented (34), but little is known regarding their effects in fluid and electrolyte metabolism. Therefore, we investigated the function of LXRs in renal Cl Ϫ secretion in both an immortalized renal principal cell model (MDCK cells) and primary cultures of mouse IMCD cells expressing both LXR␣ and LXR␤. MDCK cells were used in this study because they show characteristics of renal principal cells (15) , namely, they endogenously express CFTR (20) , respond to AVP (26), forskolin (38) , and cAMP (23), and secrete Cl Ϫ and form cysts in collagen support (16, 35) .
This study demonstrated a novel role of LXR in the downregulation of Cl Ϫ transport in renal collecting duct cells. Electrophysiological experiments revealed LXR activation in MDCK cell monolayers by both synthetic (T0901317 and GW3965) and physiological [22(R)-HC] ligands, leading to inhibition of AVP-stimulated I Cl mediated by CFTR. As the In renal collecting duct cells, AVP stimulates CFTR-mediated Cl Ϫ secretion involved in the transport of Cl Ϫ from the interstitial fluid into cells followed by transport across the apical membrane via CFTR (26, 35) . An increase in intracellular Cl Ϫ concentration is established through the functions of Na ϩ -K ϩ -2Cl Ϫ cotransporters, Na ϩ -K ϩ -ATPase, and K ϩ channels located at the basolateral membrane (30) . Changes in the activity of these channels or transporters will result in a decrease in total Cl Ϫ secretion. Therefore, one of several possible explanations for the reduction in Cl Ϫ secretion in collecting duct cells induced by activated LXR is modulation of basolateral Cl Ϫ transport. To test this notion, the contribution of basolateral transport of Cl Ϫ in LXR-activated MDCK cell monolayers was investigated. Permeabilization of the basolateral membrane to eliminate the contribution from Na ϩ -K ϩ -ATPase, Na ϩ -K ϩ -2Cl Ϫ cotransporters, and K ϩ channels in mediating the entry of Cl Ϫ into cells for further secretion (26) had no effect on the ability of LXR activation in Cl cells) and neural cells. In addition, our unpublished data showed that mRNA expression of Na ϩ -K ϩ -2Cl Ϫ cotransporters in collecting duct cells (M1 cells and primary IMCD cells) was not altered by T0901317 treatment. Taken together, these data indicate that the target of activated LXRs is not at the basolateral membrane but apparently downstream of the cAMP-dependent process since a cAMP analog produced a similar result as that obtained from AVP treatment.
The transport function of CFTR is dependent on membrane expression and the open probability of the channel. Our data demonstrated that LXR activation decreased both total and membrane protein expression but not mRNA expression of CFTR, indicating that LXR activation downregulated CFTR expression at the posttranscriptional level. However, we cannot rule out the possibility that a change in the open probability of the CFTR channel may account for the inhibition induced by LXR activation. A previous study (13) in the renal proximal tubule S2 cell line expressing human (h)OAT1 has shown that LXR activation downregulates hOAT1 protein levels without altering hOAT1 gene transcription. Recently, Caldas et al. (5) reported that the LXR agonists T0901317 and N,N-dimethyl-3␤-hydroxycholenamide inhibited the function of Na ϩ gradient-dependent phosphate transporters by decreasing Pit-2 protein and had no effect on its mRNA level. Thus, an inhibition of translation and/or a decrease in CFTR stability may account for the decrease in the activity of CFTR. Inhibition of new CFTR protein synthesis by cycloheximide abolished the inhibitory effect of LXR on CFTR-mediated Cl Ϫ transport. These data indicate that the processes downstream of CFTR protein translation, such as CFTR protein stability and trafficking, may not be the targets of LXR activation. Therefore, the possible mechanism responsible for LXR-induced inhibition of CFTR may be at the translational process, resulting in a decrease in CFTR expression and a subsequent reduction of CFTR membrane expression and transport function.
Several studies (4, 16) have demonstrated that CFTR plays a crucial role in cyst enlargement in PKD. It has previously been reported that cystic cells express LXR (14) ; therefore, an inhibition of CFTR function by LXR activation would retard cyst enlargement. Indeed, our results showed that both T0901317 and GW3965 retarded cyst enlargement compared with the untreated control. This phenomenon could be mediated, at least in part, by the decrease in CFTR content resulting in reduced fluid accumulation. Recently, peroxisome proliferator-activated receptor (PPAR)-␥, a member of the nuclear receptor superfamily, was shown to inhibit CFTR-mediated Cl Ϫ secretion in kidney collecting duct cells (26) and to attenuate the severity of PKD (3, 10) . An activation of LXRs alone or together with PPAR-␥ may have therapeutic potential in PKD treatment.
In summary, we have demonstrated that activated LXRs inhibited CFTR-mediated Cl Ϫ secretion, in part, by downregulating CFTR protein but not mRNA transcription expression levels. This may also account for the ability of LXR agonists, both endogenous and synthetic, to retard the enlargement of cysts formed from collecting duct cells. This hitherto undescribed function of activated LXRs has the potential to be further developed for the therapeutic treatment of PKD in the future.
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